Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21530751 | 0.84 | DPP4 (0.33) | DPP4 | |
| SCHEMBL6670726 | 0.77 | DPP4 (0.41) | DPP4 | |
| SCHEMBL28754700 | 0.76 | DPP4 (0.40) | DPP4 | |
| SCHEMBL29175572 | 0.76 | DPP4 (0.40) | DPP4 | |
| SCHEMBL28754699 | 0.76 | DPP4 (0.40) | DPP4 | |
| SCHEMBL8522187 | 0.76 | DPP4 (0.52) | DPP4 | |
| SCHEMBL14687259 | 0.73 | GPR84 (0.44) | — | |
| SCHEMBL19002943 | 0.71 | DPP4 (0.32) | DPP4 | |
| SCHEMBL29387119 | 0.70 | CYP3A4 (0.43) | DPP4 | |
| SCHEMBL244078 | 0.70 | CYP3A4 (0.43) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766833-B2 | Hydroformylation method and catalyst using rhodium-ruthenium dual metal and tetradentate phosphine ligand | Wuhan Catalys Technology CO., LTD (CN) | 2020-09-08 | — | — | US | disclosed |
| US-20190337866-A1 | HYDROFORMYLATION METHOD AND CATALYST USING RHODIUM-RUTHENIUM DUAL METAL AND TETRADENTATE PHOSPHINE LIGAND | Wuhan Catalys Technology CO., LTD (CN) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337866-A1 | HYDROFORMYLATION METHOD AND CATALYST USING RHODIUM-RUTHENIUM DUAL METAL AND TETRADENTATE PHOSPHINE LIGAND | HRH4, PPIP5K2, NUDT1 | DPP4 4480/4885BACE1 4762/4885 |
| US-10766833-B2 | Hydroformylation method and catalyst using rhodium-ruthenium dual metal and tetradentate phosphine ligand | HRH4, PPIP5K2, NUDT1 | DPP4 4480/4885BACE1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.